Jason Stubbs is a Nephrology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
Sponsor: Jason Stubbs, MD
- Rifaximin Therapy in Chronic Kidney Disease
Sponsor: Jason Stubbs, MD
- Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease
Sponsor: University of Kansas Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KYOWA KIRIN, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
85.7%Calcium channel blocker26.4%Amlodipine Besylate100%Part D<11 patientsACE inhibitor23.1%Lisinopril100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
14.3%Metabolic Alkalinizer14.3%Potassium Citrate Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression
University of Kansas Medical Center
FY2026$763,968R01DK122212 - Preventing vascular calcification in kidney disease
University of Kansas Medical Center
FY2026$576,256R01HL167073 - Preventing vascular calcification in kidney disease
University of Kansas Medical Center
FY2025$591,857R01HL167073
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Andrew Levey, MD
Tufts Medical Center
Laura Svetkey, MD
Duke University
Prasad Devarajan, MD
Cincinnati Children's Hospital Medical Center
Rajesh V. Thakker
Queen Mary University of London
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”